Azilsartan medoxomil: a review of its use in hypertension.
Perry CM.
Clin Drug Investig · review; journal article · DOI 10.2165/11209600-000000000-00000 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för azilsartan medoxomil. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
20 hitsAntihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil.
Bakris GL, Sica D, White WB, Cushman WC, Weber MA, Handley A, Song E, Kupfer S.
Am J Med · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.amjmed.2012.05.023Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension.
Cushman WC, Bakris GL, White WB, Weber MA, Sica D, Roberts A, Lloyd E, Kupfer S.
Hypertension · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1161/hypertensionaha.111.188284Critical evaluation of the efficacy and tolerability of azilsartan.
De Caterina AR, Harper AR, Cuculi F.
Vasc Health Risk Manag · review-article; review; journal article · DOI 10.2147/vhrm.s22589New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil.
Volpe M, Savoia C.
Integr Blood Press Control · review-article; journal article · DOI 10.2147/ibpc.s13784Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study.
Sica D, Bakris GL, White WB, Weber MA, Cushman WC, Huang P, Roberts A, Kupfer S.
J Clin Hypertens (Greenwich) · research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1111/j.1751-7176.2012.00616.xAssessment of the environmental fate and effects of azilsartan, a selective antagonist of angiotensin II type 1.
Weltman R, Brands CM, Corral E, Desmares-Koopmans MJ, Migchielsen MH, Oudhoff KA, de Roode DF.
Chemosphere · research support, non-u.s. gov't; journal article · DOI 10.1016/j.chemosphere.2012.01.053Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker.
Kajiya T, Ho C, Wang J, Vilardi R, Kurtz TW.
J Hypertens · research support, non-u.s. gov't; journal article; research support, n.i.h., extramural · DOI 10.1097/hjh.0b013e32834c46fdAzilsartan medoxomil: a new angiotensin II receptor antagonist for treatment of hypertension.
Baker WL, White WB.
Ann Pharmacother · systematic review; journal article · DOI 10.1345/aph.1q468Azilsartan medoxomil: a new Angiotensin receptor blocker.
Zaiken K, Cheng JW.
Clin Ther · review; journal article · DOI 10.1016/j.clinthera.2011.10.007Azilsartan Medoxomil (Edarbi): The Eighth Angiotensin II Receptor Blocker.
Jones JD, Jackson SH, Agboton C, Martin TS.
P T · research-article; journal articleAzilsartan medoxomil for the treatment of hypertension.
Vasiliou S.
Drugs Today (Barc) · review; journal article · DOI 10.1358/dot.2011.47.9.1688573The angiotensin receptor blocker, azilsartan medoxomil (TAK-491), suppresses vascular wall expression of plasminogen activator inhibitor type-I protein potentially facilitating the stabilization of atherosclerotic plaques.
French CJ, Zaman AK, Sobel BE.
J Cardiovasc Pharmacol · research support, non-u.s. gov't; journal article; research support, n.i.h., extramural · DOI 10.1097/fjc.0b013e31821dcbeaAntihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models.
Kusumoto K, Igata H, Ojima M, Tsuboi A, Imanishi M, Yamaguchi F, Sakamoto H, Kuroita T, Kawaguchi N, Nishigaki N, Nagaya H.
Eur J Pharmacol · comparative study; journal article · DOI 10.1016/j.ejphar.2011.07.014Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring.
Sica D, White WB, Weber MA, Bakris GL, Perez A, Cao C, Handley A, Kupfer S.
J Clin Hypertens (Greenwich) · research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1111/j.1751-7176.2011.00482.xNew drugs. Azilsartan medoxomil, belimumab, and lurasidone hydrochloride.
Hussar DA, Shah A.
J Am Pharm Assoc (2003) · journal article · DOI 10.1331/japha.2011.11522Azilsartan medoxomil (Edarbi) the eighth ARB.
Författaruppgift saknas
Med Lett Drugs Ther · comparative study; journal articleThe comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure.
Bakris GL, Sica D, Weber M, White WB, Roberts A, Perez A, Cao C, Kupfer S.
J Clin Hypertens (Greenwich) · research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1111/j.1751-7176.2010.00425.xEffects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
White WB, Weber MA, Sica D, Bakris GL, Perez A, Cao C, Kupfer S.
Hypertension · comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1161/hypertensionaha.110.163402Gateways to clinical trials.
Tomillero A, Moral MA.
Methods Find Exp Clin Pharmacol · bibliography; journal article · DOI 10.1358/mf.2010.32.7.1549223